Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of BRAF -mutant advanced melanoma: A matching-adjusted indirect comparison
Open Access
- 14 December 2025
- journal article
- Published by BMJ in BMJ Oncology
- Vol. 4 (1) , e000912
Abstract
Background: Dual immuno-oncology (IO) therapy or BRAF/MEK inhibitor combinations are approved first-line (1L) treatment options for BRAF- mutant advanced melanoma. In the absence of head-to-head trials comparing 1L nivolumab plus relatlimab (NIVO+RELA) to BRAF/MEK inhibitors, we compared its efficacy to dabrafenib+trametinib (DAB+TRAM), encorafenib+binimetinib (ENCO+BINI), vemurafenib+cobimetinib (VEM+COBI) and atezolizumab (ATEZO)+VEM+COBI using matching-adjusted indirect comparisons (MAICs). Methods: Patient-level data for NIVO+RELA from the RELATIVITY-047 trial ( BRAF -mutant subset) and aggregate data from the COMBI-d/v, COLUMBUS, coBRIM and IMspire150 trials were used. Adults with untreated BRAF- mutant advanced melanoma receiving 1L therapy were included. Separate unanchored MAICs were conducted to compare outcomes between NIVO+RELA versus comparators. MAICs matched on baseline characteristics per data availability and clinical relevance (age, sex, metastatic stage, prior IO, brain metastases, tumour size, etc.). Overall survival (OS) and investigator-assessed progression-free survival (PFS) were compared using weighted Cox proportional hazards models and, due to violation of the proportional hazards assumption, interval Cox models with boundaries at 12 (doublets) or 24 (ATEZO+VEM+COBI) months from treatment initiation. Investigator-assessed overall response rate (ORR) and safety outcomes (any adverse event (AE), grade 3/4 AEs, AEs leading to discontinuation, specific AEs) were compared via ORs and risk differences (RDs), respectively. Results: BRAF -mutant patients from RELATIVITY-047 (n=136) were matched to patients who received DAB+TRAM (n=563), ENCO+BINI (n=192), VEM+COBI (n=247) or ATEZO+VEM+COBI (n=256). Post-matching, NIVO+RELA was associated with longer OS after 12 months versus DAB+TRAM (HR (95% CI) 0.47 (0.31 to 0.70)), ENCO+BINI (0.51 (0.32 to 0.83)) and VEM+COBI (0.41 (0.26 to 0.62)) and at any time versus ATEZO+VEM+COBI (0.68 (0.48–0.98)). PFS was shorter versus DAB+TRAM (1.36 (0.96 to 1.94)), ENCO+BINI (1.72 (1.13 to 2.61)) and VEM+COBI (1.27 (0.89 to 1.81)) in the first 12 months but favoured NIVO+RELA after 12 months (0.56 (0.33 to 0.93), 0.63 (0.28 to 1.45) and 0.41 (0.24 to 0.70)). PFS was similar versus ATEZO+VEM+COBI through 24 months (1.21 (0.87 to 1.68)) and favoured NIVO+RELA beyond 24 months (0.45 (0.19 to 1.07)). ORR was lower with NIVO+RELA versus all comparators. Grade 3/4 AEs were less frequent with NIVO+RELA versus DAB+TRAM (RD (95% CI) −20.1% (−30.6 to −9.5)), ENCO+BINI (−29.2% (-42.2 to −16.3)), VEM+COBI (−36.9% (−47.5 to −26.3)) and ATEZO+VEM+COBI (percentage: 40.0% vs 74.9%). Conclusions: These MAICs suggest that 1L dual IO therapy with NIVO+RELA confers a long-term OS advantage in BRAF -mutant advanced melanoma compared with BRAF/MEK inhibitor combinations despite lower ORR, consistent with prior evidence for 1L NIVO+IPI in this setting. As unanchored analyses, potential residual confounding remains, and results should be interpreted cautiously.Keywords
Funding Information
- Bristol-Myers Squibb (N/A)
This publication has 33 references indexed in Scilit:
- CO62 Network Meta-Analysis (NMA) of Immuno-Oncology (IO) Treatments for First-Line (1L) Advanced or Metastatic MelanomaValue in Health, 2023
- 1113P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanomaAnnals of Oncology, 2023
- Activity and safety of first-line treatments for advanced melanoma: A network meta-analysisEuropean Journal of Cancer, 2023
- Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 studyThe Lancet Oncology, 2022
- A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆ESMO Open, 2021
- Treatment of Advanced Melanoma in 2020 and BeyondJournal of Investigative Dermatology, 2021
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2020
- Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanomaEuropean Journal of Cancer, 2020
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2018
- Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trialThe Lancet Oncology, 2017